Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Abstract: Deep learning excels in natural image object detection, but remote sensing images face challenges like multidirectional objects and neighborhood interference. Existing methods use shared ...

Diego is a writer and editor with over six years of experience covering games. He's mainly focused on guides, but he's done reviews, features, news, and everything in between. A fan of all genres, you ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. 10 stocks we like better than Recursion ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...

Shares of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to predict ...

A parameter cannot be found that matches parameter name 'DisableWAM'. At C:\Program Files\WindowsPowerShell\Modules\ExchangeOnlineManagement\3.7.2\netFramework\ExchangeOnlineManagement.psm1:560 ...

A new JavaScript obfuscation method utilizing invisible Unicode characters to represent binary values is being actively abused in phishing attacks targeting affiliates of an American political action ...

Google says it has begun requiring users to turn on JavaScript, the widely used programming language to make web pages interactive, in order to use Google Search. In ...

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from the ...

Recursion announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.